Oncolytic adenovirus coding for bispecific T cell engager against human MUC-1 potentiates T cell response against solid tumors

Immunotherapy with bispecific T cell engagers has shown efficacy in patients with hematologic malignancies and uveal melanoma. Antitumor effects of bispecific T cell engagers in most solid tumors are limited due to their short serum half-life and insufficient tumor concentration. We designed a novel...

Cijeli opis

Bibliografski detalji

Glavni autori:	Saru Basnet, Joao M. Santos, Dafne C.A. Quixabeira, James H.A. Clubb, Susanna A.M. Grönberg-Vähä-Koskela, Victor Arias, Santeri Pakola, Tatiana V. Kudling, Camilla Heiniö, Riikka Havunen, Victor Cervera-Carrascon, Suvi Sorsa, Marjukka Anttila, Anna Kanerva, Akseli Hemminki
Format:	Artigo
Jezik:	Inglês
Izdano:	Elsevier 2023-03-01
Serija:	Molecular Therapy: Oncolytics
Teme:	oncolytic virus adenovirus bispecific T cell engager MUC1 immunotherapy
Online pristup:	http://www.sciencedirect.com/science/article/pii/S2372770522001553
Oznake:	Dodaj oznaku Bez oznaka, Budi prvi tko označuje ovaj zapis!